The Biological Disappearance Rate of Prothrombin, Factors VII, IX and X from Plasma in Hypothyroidism, Hyperthyroidism, and During Fever

E. A Loeliger; B van der Esch; Mieke J Mattern; H. C Hemker

doi:10.1055/s-0038-1654782

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1963; 10(02): 267-277
DOI: 10.1055/s-0038-1654782

Originalarbeiten — Original Article — Travaux Originaux

Schattauer GmbH

The Biological Disappearance Rate of Prothrombin, Factors VII, IX and X from Plasma in Hypothyroidism, Hyperthyroidism, and During Fever

E. A Loeliger

¹Haematology Section of the Department of Internal Medicine (Head: Prof. J. Mulder, M.D.), University Hospital, and the Thrombosis Service (Head: E. A. Loeliger, M.D.,), Leyden, The Netherlands

,

B van der Esch

¹Haematology Section of the Department of Internal Medicine (Head: Prof. J. Mulder, M.D.), University Hospital, and the Thrombosis Service (Head: E. A. Loeliger, M.D.,), Leyden, The Netherlands

,

Mieke J Mattern

¹Haematology Section of the Department of Internal Medicine (Head: Prof. J. Mulder, M.D.), University Hospital, and the Thrombosis Service (Head: E. A. Loeliger, M.D.,), Leyden, The Netherlands

,

H. C Hemker

¹Haematology Section of the Department of Internal Medicine (Head: Prof. J. Mulder, M.D.), University Hospital, and the Thrombosis Service (Head: E. A. Loeliger, M.D.,), Leyden, The Netherlands

› Institutsangaben

Abstract

Summary

The biological disappearance rate of coagulation factors II, VIT, IX and X from plasma is decreased in myxoedema and increased in thyreotoxicosis. In patients with elevated body temperatures, an increase of up to three times the normal rate was observed. The clinical implications of these findings are briefly discussed.

Volltext

Referenzen

References
1 Davies J. W. L, Ricketts C. R, Bull J. P. Studies of plasma protein metabolism. Part I: Albumin in burned and injured patients. Clin. Sci. 23: 411 1962;
2 vander Esch B. Thesis. Leiden. 1963
3 Hart ChH.. Personal communication. 1963
4 Hensen A, Loeliger E. A. Antithrombin III, its metabolism and its function in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg.). 09. suppl. 1 1963
5 Loeliger E. A, Hensen A. Substitution therapy in haemophilia B. Thrombos. Diathes. haemorrh. (Stuttg.) 06: 391 1961;
6 Loeliger E. A, van der Esch B, Mattern M. J, den Bra-bander A. S. A. Behaviour of factors II, VII, IX, and X during long-term treatment with coumarin. Thrombos. Diathes. haemorrh. (Stuttg.) 09: 74 1963;
7 Loeliger E. A. et al. In preparation.
8 Nilsson I. M, Blombäck M, Ramgren O. Haemophilia in Sweden. VI. Treatment of haemophilia A with the human antihaemophilic factor preparation (fraction I—0). Acta med. scand. 171 suppl. 379, 61 1962;
9 Owren P. A, Aas K. The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest. 03: 169 1951;
10 Quick A. J. The physiology and pathology of hemostasis. Henry Kimpton; London: 1951